Reaction
Glomerulonephritis Membranoproliferative reporting signals
As of the last recalculation, Glomerulonephritis Membranoproliferative appears in 519 FAERS reports alongside 19 co-occurring drug terms. The strongest observed disproportionality signal is SOFOSBUVIR (PRR 71.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sofosbuvir | 33 | 71.6 | 71.7 |
| Ampicillin | 14 | 69.6 | 69.8 |
| Ampicillin Sodium | 14 | 69.6 | 69.8 |
| Basiliximab | 16 | 56.3 | 56.3 |
| Anti-Thymocyte Globulin (Rabbit) | 11 | 55.8 | 55.9 |
| Tobramycin Solution | 13 | 44.5 | 44.5 |
| Tobramycin Sulfate | 13 | 43.2 | 43.2 |
| Mycophenolic Acid | 31 | 41.2 | 41.3 |
| Tacrolimus Ointment 0.1% | 98 | 38.7 | 38.7 |
| Tacrolimus Extended-Release Capsules | 98 | 38.6 | 38.6 |
| Mycophenilic Acid | 19 | 38.1 | 38.2 |
| Mycophenolate Mofetil | 101 | 36.8 | 36.8 |
| Mycophenolate Mofetil Hydrochloride | 101 | 36.7 | 36.7 |
| Tacrolimus | 112 | 36.3 | 36.3 |
| Eculizumab | 29 | 22.6 | 22.6 |
| Tobramycin | 13 | 22.2 | 22.2 |
| Ribavirin | 24 | 15.6 | 15.7 |
| Ledipasvir And Sofosbuvir | 5 | 10.5 | 10.5 |
| Aflibercept | 6 | 7.8 | 7.8 |